I-Mab Biopharma , a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics ...
I-Mab Biopharma announced the Investigational New Drug (IND) application for the initiation of a Phase 1 clinical study for TJD5 in patients with advanced solid tumor has cleared the required 30 day review by the U.S. Food and Drug Administration (FDA)...